JP2023500385A - 医薬組合せ物およびその使用 - Google Patents

医薬組合せ物およびその使用 Download PDF

Info

Publication number
JP2023500385A
JP2023500385A JP2022526767A JP2022526767A JP2023500385A JP 2023500385 A JP2023500385 A JP 2023500385A JP 2022526767 A JP2022526767 A JP 2022526767A JP 2022526767 A JP2022526767 A JP 2022526767A JP 2023500385 A JP2023500385 A JP 2023500385A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500385A5 (https=
JPWO2021093764A5 (https=
Inventor
ジャン，ジュアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CStone Pharmaceuticals Suzhou Co Ltd
Original Assignee
CStone Pharmaceuticals Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CStone Pharmaceuticals Suzhou Co Ltd filed Critical CStone Pharmaceuticals Suzhou Co Ltd
Publication of JP2023500385A publication Critical patent/JP2023500385A/ja
Publication of JP2023500385A5 publication Critical patent/JP2023500385A5/ja
Publication of JPWO2021093764A5 publication Critical patent/JPWO2021093764A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022526767A 2019-11-11 2020-11-11 医薬組合せ物およびその使用 Pending JP2023500385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/117155 2019-11-11
CN2019117155 2019-11-11
PCT/CN2020/128083 WO2021093764A1 (en) 2019-11-11 2020-11-11 Pharmaceutical combination and use thereof

Publications (3)

Publication Number Publication Date
JP2023500385A true JP2023500385A (ja) 2023-01-05
JP2023500385A5 JP2023500385A5 (https=) 2023-11-20
JPWO2021093764A5 JPWO2021093764A5 (https=) 2023-11-20

Family

ID=75911807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526767A Pending JP2023500385A (ja) 2019-11-11 2020-11-11 医薬組合せ物およびその使用

Country Status (11)

Country Link
US (1) US20220387417A1 (https=)
EP (1) EP4031179A4 (https=)
JP (1) JP2023500385A (https=)
KR (1) KR20220103961A (https=)
CN (1) CN114901309A (https=)
AU (1) AU2020383580A1 (https=)
BR (1) BR112022009042A2 (https=)
CA (1) CA3160526A1 (https=)
IL (1) IL292646A (https=)
MX (1) MX2022005034A (https=)
WO (1) WO2021093764A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450616A3 (en) * 2016-09-21 2025-01-01 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (pd-1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053709A1 (en) * 2016-09-21 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. The novel monoclonal antibodies to programmed death 1 (pd-1)
JP2018512391A (ja) * 2015-03-04 2018-05-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
JP2018527949A (ja) * 2015-08-06 2018-09-27 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 新規抗ｐｄ−ｌ１抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
KR102655301B1 (ko) * 2017-04-06 2024-04-08 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
CN110536694A (zh) * 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
CN109731019B (zh) * 2019-03-07 2021-07-16 康赋葆(深圳)生物医药科技有限公司 一种具有化疗增效作用的组合物，包括组成、制备及应用
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018512391A (ja) * 2015-03-04 2018-05-17 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
JP2018527949A (ja) * 2015-08-06 2018-09-27 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 新規抗ｐｄ−ｌ１抗体
WO2018053709A1 (en) * 2016-09-21 2018-03-29 Wuxi Biologics (Shanghai) Co., Ltd. The novel monoclonal antibodies to programmed death 1 (pd-1)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. Vol.27 (Supplement 6), JPN6024045333, 2016, pages 1 - 14, ISSN: 0005457833 *
INTERNATIONAL JOURNAL OF CANCER, vol. 144, JPN6024045335, May 2019 (2019-05-01), pages 2266 - 2278, ISSN: 0005457831 *
PLOS ONE, vol. 14, no. 2, JPN6024045334, February 2019 (2019-02-01), pages 0212513 - 1, ISSN: 0005457832 *

Also Published As

Publication number Publication date
BR112022009042A2 (pt) 2022-10-11
CN114901309A (zh) 2022-08-12
AU2020383580A1 (en) 2022-05-12
US20220387417A1 (en) 2022-12-08
EP4031179A1 (en) 2022-07-27
CA3160526A1 (en) 2021-05-20
KR20220103961A (ko) 2022-07-25
IL292646A (en) 2022-07-01
WO2021093764A1 (en) 2021-05-20
MX2022005034A (es) 2022-05-16
EP4031179A4 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US20210024635A1 (en) Anti-wt1/hla-specific antibodies
WO2019024911A1 (zh) B7h3抗体-药物偶联物及其医药用途
JP2021530251A (ja) 新規な抗体ならびにそれを調製および使用するための方法
CN112867507A (zh) 新型抗sirpa抗体
KR20160097336A (ko) 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
CN112105642B (zh) 抗pd-1抗体及其用途
KR102885855B1 (ko) 항-pd-1 항체 및 이의 용도
JP2017519501A (ja) 抗Ａｘｌ抗体
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
JP7479281B2 (ja) 抗ｏｘ４０抗体及びその用途
WO2019137397A1 (zh) Pd-l1抗体、其抗原结合片段及医药用途
TWI865753B (zh) 雙特異性抗體及其製造方法
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
WO2022098771A1 (en) Multispecific antibodies and uses thereof
CN121108344A (zh) 抗cd3抗体以及其用途
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN115998900A (zh) 抗trop-2抗体药物偶联物及其医药用途
JP2025535503A (ja) 抗ｃｃｒ８抗体及びその使用
JP2023500385A (ja) 医薬組合せ物およびその使用
HK40071307A (en) Pharmaceutical combination and use thereof
WO2025201493A1 (zh) Dll3结合分子及其用途
CN119451991A (zh) 一种新型多特异肿瘤抑制剂的开发和应用
CN120693178A (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527